🇺🇸 FDA
Patent

US 10640535

Identification of MHC class I phospho-peptide antigens from breast cancer utilizing SHLA technology and complementary enrichment strategies

granted A61KA61K38/00A61K39/0011

Quick answer

US patent 10640535 (Identification of MHC class I phospho-peptide antigens from breast cancer utilizing SHLA technology and complementary enrichment strategies) held by The Board of Regents of the University of Oklahoma expires Mon Apr 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Oklahoma
Grant date
Tue May 05 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
55
CPC classes
A61K, A61K38/00, A61K39/0011, A61P, A61P35/00